A major factor hindering the exploration of adoptive immunotherapy in preclinical settings is
the limited availability of tumor-reactive human T cells. Here we developed a humanized …

Abstract Both CD8+ and CD4+ T cells have demonstrated roles in antitumor immune
response in many animal tumor systems. In many human tumor systems, although abundant …

Background Adoptive cell therapy with peripheral blood T cells expressing transgenic T-cell
receptors (TCRs) is an innovative therapeutic approach for solid malignancies. We …

Current tumor immunotherapy approaches include the genetic modification of peripheral T
cells to express tumor antigen-specific T-cell receptors (TCRs). The approach, tested in …

Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive
cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous …

Peripheral blood lymphocytes (PBL) genetically modified to express T cell receptors (TCR)
specific to known melanoma antigens, such as melanoma antigen recognized by T cells-1 …

Adoptive cell therapy using T-cell receptor (TCR)–engineered T cells is a clinically feasible
and promising approach to target tumors, but is currently faced with compromised antitumor …

The murine melanoma B16 expresses the murine counterpart of the human MART-1/Melan-
A (MART-1) antigen, sharing a 68.6% amino acid sequence identity. In this study, mice were …

Adoptive cell transfer (ACT) of genetically engineered T cells expressing cancer-specific T-
cell receptors (TCR) is a promising cancer treatment. Here, we investigate the in vivo …

The tumor-associated-Ag MART-1 is expressed by most human melanomas. The genes
encoding an αβ TCR from a MART-1-specific, HLA-A2-restricted, human T cell clone have …